Roivant Sciences Ltd. (ROIV) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Roivant Sciences Ltd.

ROIV

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

8B

Biotechnology

Next Earning date - 29 May 2025

8B

Biotechnology

Next Earning date - 29 May 2025

11.01USD

0.01 ( 0.09%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

58

Volume Buzz

28%

Earning Acce

No

Dist 52w H.

16%

Quote Panel

Updated April 27, 2025

1W 9.66 % 1M 6.07 % 3M -1.26 % 1Y -1.08 %

Key Metrics

Market Cap
7.86B
Shares Outstanding
713.55M
Share in Float
438.66M
Dividende
0

Earning Date
29 May 2025
Price Target
11.01
Average Volume
6.17M
Beta
1.252

Range
8.73-13.055
Industry
Biotechnology
Website
https://roivant.com
Sector
Healthcare

Fundamentals

Relative Strength

ROIV

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q4.23

N/A

-0.21
vs -0.49

Q1.24

N/A

-0.23
vs -0.20

Q2.24

N/A

-0.18
vs -0.38

Q3.24

N/A

-0.29
vs -0.26

Q4.24

N/A

-0.13
vs -0.21

Q1.25

N/A

-0.26
vs -0.23

Q2.25

N/A

-0.24
vs -0.18

Sales Growth

YoY

Current

Estimates

Q4.23

+118%

37.1M vs 17.1M

Q1.24

+6%

28.9M vs 27.4M

Q2.24

+155%

55.1M vs 21.6M

Q3.24

-88%

4.5M vs 37.1M

Q4.24

-76%

9M vs 37.1M

Q1.25

+87%

54.1M vs 28.9M

Q2.25

-91%

5.2M vs 55.1M

Return on Equity

QoQ

Q1.23

-3%

-0.03
vs -0.37

Q2.23

-32%

-0.32
vs -0.03

Q3.23

-32%

-0.32
vs -0.32

Q4.23

+84%

0.84
vs -0.32

Q1.24

-3%

-0.03
vs 0.84

Q2.24

+2%

0.02
vs -0.03

Q3.24

-4%

-0.04
vs 0.02

Q4.24

+3%

0.03
vs -0.04

Institutionnal Ownership

QoQ

Q1.23

154

154
vs 116

33%

Q2.23

187

187
vs 154

21%

Q3.23

218

218
vs 187

17%

Q4.23

241

241
vs 218

11%

Q1.24

268

268
vs 241

11%

Q2.24

307

307
vs 268

15%

Q3.24

309

309
vs 307

1%

Q4.24

327

327
vs 309

6%

Earnings Growth

Latest News

ROIV

globenewswire.com

7 hours ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

ROIV

globenewswire.com

7 hours ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

ROIV

globenewswire.com

7 hours ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

ROIV

investors.com

9 hours ago

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.

ROIV

seekingalpha.com

12 hours ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

ROIV

globenewswire.com

16 hours ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs